Imagine a health center promising groundbreaking treatments for devastating diseases like ALS and Alzheimer's, only to be accused of putting patients at risk. This is the shocking reality surrounding Dr. Dayan Goodenowe and his controversial Moose Jaw health center. The U.S. Food and Drug Administration (FDA) has issued a stern warning, alleging that Goodenowe's recent clinical trial of his supplements, ProdromeNeuro, endangered the safety of research participants. But here's where it gets even more concerning: Goodenowe failed to obtain the necessary regulatory approvals before conducting the study, raising serious ethical and legal questions. And this is the part most people miss: despite the controversy, Goodenowe is expanding his operations globally, with plans to enter China and Japan. Is this a pioneer pushing boundaries or a reckless entrepreneur prioritizing profit over patient safety? Let's delve into the details.
On January 20th, the FDA publicly reprimanded Goodenowe and his company, Prodrome Sciences USA, LLC, for conducting a clinical trial without filing an Investigational New Drug (IND) application. This crucial step requires researchers to provide evidence, including animal testing data, demonstrating the study's safety for human subjects. The FDA's warning letter highlights the potential risks to participants and casts doubt on the validity of the study's findings. Interestingly, while the FDA warns of potential harm, no adverse events were reported among the 29 participants enrolled in the trial between 2020 and 2021. This study, published in Frontiers in Cell and Developmental Biology, claimed that ProdromeNeuro improved mobility and cognitive function in dementia patients. However, the journal has since issued an 'expression of concern,' acknowledging potential regulatory breaches and launching its own investigation.
This isn't Goodenowe's first brush with controversy. Last year, CBC investigations exposed questionable claims about his supplements' effectiveness, particularly regarding ALS treatment. American patients paid exorbitant fees for his program, only to experience worsening symptoms. Goodenowe's response? He sued CBC for defamation, alleging a conspiracy against his business. The saga continues with ongoing investigations by Moose Jaw police, Saskatchewan's consumer affairs regulator, and the College of Physicians and Surgeons.
The heart of the matter lies in the blurred line between natural supplements and drugs. Goodenowe argues that ProdromeNeuro, derived from shark liver oil, is a dietary supplement exempt from IND requirements. The FDA disagrees, stating that any substance intended to treat or prevent disease falls under drug regulations. This distinction is crucial, as it determines the level of scrutiny and patient protection. Research ethics expert Janice Parente emphasizes the gravity of the situation, stating that Goodenowe's actions amount to breaking the law, not merely a procedural oversight.
Goodenowe's defense? He blames Sterling IRB, the company responsible for ethics and protocol review, for missing the IND requirement. However, critics argue that the responsibility ultimately lies with the researcher. Timothy Caulfield, a renowned expert in medical research ethics, suggests that Goodenowe's actions reflect either naivety or deliberate circumvention of regulations—neither of which inspires confidence.
As Goodenowe expands his empire, with a $100 million project in Moose Jaw and ventures into Asia, questions linger. How did his study get published without proper regulatory approvals? Frontiers journal claims reliance on Sterling IRB's review, but Parente counters that journals must conduct their due diligence. Goodenowe's partnership with Dr. Sheldon Jordan, a board-certified neurologist, adds another layer of complexity. Jordan's office claims to have severed ties with Goodenowe years ago, yet he remains a co-author on the study.
Health Canada has also weighed in, stating that Goodenowe has not obtained the necessary licenses to manufacture his supplements in Canada. Despite this, he plans to produce plasmalogen precursors in Moose Jaw for the Chinese market. With so many red flags, one must wonder: are Goodenowe's actions a bold pursuit of medical breakthroughs or a dangerous disregard for patient welfare? The answer may lie in the ongoing investigations and the public's demand for accountability. What do you think? Is Goodenowe a visionary or a risk-taker gone too far? Share your thoughts in the comments below.
